Past PSI Events

Conferences

PSI/EFSPI Webinar: Quantitative benefit-risk assessment using MultiCriteria Decision Analysis (MCDA) and its extensions: practical application

Time: 14:00 - 15:30 UK Time

Presenters: Gaelle Saint-Hilary and Stephanie Cadour

Click here to view the presentation slides.

Click here for the programme and slides.

Abstract

Several quantitative methodologies have been proposed to support decision-making in drug development. In particular, MultiCriteria Decision Analysis (MCDA) is a useful tool to assess the benefit-risk balance of medicines according to the performances of the treatments on several criteria, accounting for the preferences of the decision-makers regarding the relative importance of these criteria. The EMA Benefit-Risk Methodology Project suggested that it is one of the most comprehensive among the quantitative methodologies they considered, and it is also recommended by several highly profiled expert groups. While MCDA requires the exact elicitation of the weights of the criteria according to the preferences of the decision-makers, extended versions of MCDA have been proposed, such as Stochastic Multicriteria Acceptability Analysis (SMAA) and Dirichlet SMAA, where the weights are considered as random variables to account for some uncertainty in the weight assignment.

This webinar proposes a very concrete illustration of MCDA and of the extended models SMAA and Dirichlet SMAA using case-studies. We will present how to derive a benefit-risk utility score for each treatment, how to compare several treatments, how to present the results and how to conduct sensitivity analyses. The differences between the models will be highlighted, and some R code will be presented and shared after the presentation.



About the Presenter: Gaelle Saint-Hilary

Stephanie CadourGaelle Saint-Hilary works in statistics for the pharmaceutical industry since 2006. She is currently completing a PhD on “Quantitative Decision-Making in Drug Development”, sponsored by Servier, at the Polytechnic University of Turin (Italy). Before that, she worked as biostatistician in the industry, first at Servier for 5 years and then at Novartis Oncology for 4 years. She was responsible for the clinical development and the licensing of medicinal products in neuropsychiatry and leukemia, and her main scientific interests were benefit-risk assessment, network meta-analyses, multiple test procedures, simulation models of time-to-event data and survival analysis in presence of intercurrent events. The development and the promotion of quantitative methods for drug benefit-risk assessments is one of the major topics she considers during her PhD, with the final goal of enhancing decision-making throughout the drug life-cycle. 





About the Presenter: Stephanie Cadour

Gaelle Saint-HilaryGraduated in 2011, Stéphanie Cadour works as a biostatistician at Servier (France) since then. She was initially responsible for the statistical aspects of phase II and III clinical studies conducted in the therapeutic areas of neuropsychiatry and diabetes. She is now working on early phase studies in the field of oncology. In parallel of these activities, Stephanie developed skills on meta-analyses as well as on quantitative approaches for benefit-risk assessment on which she has been working on since 2011.




To access the recording, please visit the Video-on-Demand Library.

Scientific Meetings

PSI/EFSPI Webinar: Quantitative benefit-risk assessment using MultiCriteria Decision Analysis (MCDA) and its extensions: practical application

Time: 14:00 - 15:30 UK Time

Presenters: Gaelle Saint-Hilary and Stephanie Cadour

Click here to view the presentation slides.

Click here for the programme and slides.

Abstract

Several quantitative methodologies have been proposed to support decision-making in drug development. In particular, MultiCriteria Decision Analysis (MCDA) is a useful tool to assess the benefit-risk balance of medicines according to the performances of the treatments on several criteria, accounting for the preferences of the decision-makers regarding the relative importance of these criteria. The EMA Benefit-Risk Methodology Project suggested that it is one of the most comprehensive among the quantitative methodologies they considered, and it is also recommended by several highly profiled expert groups. While MCDA requires the exact elicitation of the weights of the criteria according to the preferences of the decision-makers, extended versions of MCDA have been proposed, such as Stochastic Multicriteria Acceptability Analysis (SMAA) and Dirichlet SMAA, where the weights are considered as random variables to account for some uncertainty in the weight assignment.

This webinar proposes a very concrete illustration of MCDA and of the extended models SMAA and Dirichlet SMAA using case-studies. We will present how to derive a benefit-risk utility score for each treatment, how to compare several treatments, how to present the results and how to conduct sensitivity analyses. The differences between the models will be highlighted, and some R code will be presented and shared after the presentation.



About the Presenter: Gaelle Saint-Hilary

Stephanie CadourGaelle Saint-Hilary works in statistics for the pharmaceutical industry since 2006. She is currently completing a PhD on “Quantitative Decision-Making in Drug Development”, sponsored by Servier, at the Polytechnic University of Turin (Italy). Before that, she worked as biostatistician in the industry, first at Servier for 5 years and then at Novartis Oncology for 4 years. She was responsible for the clinical development and the licensing of medicinal products in neuropsychiatry and leukemia, and her main scientific interests were benefit-risk assessment, network meta-analyses, multiple test procedures, simulation models of time-to-event data and survival analysis in presence of intercurrent events. The development and the promotion of quantitative methods for drug benefit-risk assessments is one of the major topics she considers during her PhD, with the final goal of enhancing decision-making throughout the drug life-cycle. 





About the Presenter: Stephanie Cadour

Gaelle Saint-HilaryGraduated in 2011, Stéphanie Cadour works as a biostatistician at Servier (France) since then. She was initially responsible for the statistical aspects of phase II and III clinical studies conducted in the therapeutic areas of neuropsychiatry and diabetes. She is now working on early phase studies in the field of oncology. In parallel of these activities, Stephanie developed skills on meta-analyses as well as on quantitative approaches for benefit-risk assessment on which she has been working on since 2011.




To access the recording, please visit the Video-on-Demand Library.

Training Courses

PSI/EFSPI Webinar: Quantitative benefit-risk assessment using MultiCriteria Decision Analysis (MCDA) and its extensions: practical application

Time: 14:00 - 15:30 UK Time

Presenters: Gaelle Saint-Hilary and Stephanie Cadour

Click here to view the presentation slides.

Click here for the programme and slides.

Abstract

Several quantitative methodologies have been proposed to support decision-making in drug development. In particular, MultiCriteria Decision Analysis (MCDA) is a useful tool to assess the benefit-risk balance of medicines according to the performances of the treatments on several criteria, accounting for the preferences of the decision-makers regarding the relative importance of these criteria. The EMA Benefit-Risk Methodology Project suggested that it is one of the most comprehensive among the quantitative methodologies they considered, and it is also recommended by several highly profiled expert groups. While MCDA requires the exact elicitation of the weights of the criteria according to the preferences of the decision-makers, extended versions of MCDA have been proposed, such as Stochastic Multicriteria Acceptability Analysis (SMAA) and Dirichlet SMAA, where the weights are considered as random variables to account for some uncertainty in the weight assignment.

This webinar proposes a very concrete illustration of MCDA and of the extended models SMAA and Dirichlet SMAA using case-studies. We will present how to derive a benefit-risk utility score for each treatment, how to compare several treatments, how to present the results and how to conduct sensitivity analyses. The differences between the models will be highlighted, and some R code will be presented and shared after the presentation.



About the Presenter: Gaelle Saint-Hilary

Stephanie CadourGaelle Saint-Hilary works in statistics for the pharmaceutical industry since 2006. She is currently completing a PhD on “Quantitative Decision-Making in Drug Development”, sponsored by Servier, at the Polytechnic University of Turin (Italy). Before that, she worked as biostatistician in the industry, first at Servier for 5 years and then at Novartis Oncology for 4 years. She was responsible for the clinical development and the licensing of medicinal products in neuropsychiatry and leukemia, and her main scientific interests were benefit-risk assessment, network meta-analyses, multiple test procedures, simulation models of time-to-event data and survival analysis in presence of intercurrent events. The development and the promotion of quantitative methods for drug benefit-risk assessments is one of the major topics she considers during her PhD, with the final goal of enhancing decision-making throughout the drug life-cycle. 





About the Presenter: Stephanie Cadour

Gaelle Saint-HilaryGraduated in 2011, Stéphanie Cadour works as a biostatistician at Servier (France) since then. She was initially responsible for the statistical aspects of phase II and III clinical studies conducted in the therapeutic areas of neuropsychiatry and diabetes. She is now working on early phase studies in the field of oncology. In parallel of these activities, Stephanie developed skills on meta-analyses as well as on quantitative approaches for benefit-risk assessment on which she has been working on since 2011.




To access the recording, please visit the Video-on-Demand Library.

Journal Club

PSI/EFSPI Webinar: Quantitative benefit-risk assessment using MultiCriteria Decision Analysis (MCDA) and its extensions: practical application

Time: 14:00 - 15:30 UK Time

Presenters: Gaelle Saint-Hilary and Stephanie Cadour

Click here to view the presentation slides.

Click here for the programme and slides.

Abstract

Several quantitative methodologies have been proposed to support decision-making in drug development. In particular, MultiCriteria Decision Analysis (MCDA) is a useful tool to assess the benefit-risk balance of medicines according to the performances of the treatments on several criteria, accounting for the preferences of the decision-makers regarding the relative importance of these criteria. The EMA Benefit-Risk Methodology Project suggested that it is one of the most comprehensive among the quantitative methodologies they considered, and it is also recommended by several highly profiled expert groups. While MCDA requires the exact elicitation of the weights of the criteria according to the preferences of the decision-makers, extended versions of MCDA have been proposed, such as Stochastic Multicriteria Acceptability Analysis (SMAA) and Dirichlet SMAA, where the weights are considered as random variables to account for some uncertainty in the weight assignment.

This webinar proposes a very concrete illustration of MCDA and of the extended models SMAA and Dirichlet SMAA using case-studies. We will present how to derive a benefit-risk utility score for each treatment, how to compare several treatments, how to present the results and how to conduct sensitivity analyses. The differences between the models will be highlighted, and some R code will be presented and shared after the presentation.



About the Presenter: Gaelle Saint-Hilary

Stephanie CadourGaelle Saint-Hilary works in statistics for the pharmaceutical industry since 2006. She is currently completing a PhD on “Quantitative Decision-Making in Drug Development”, sponsored by Servier, at the Polytechnic University of Turin (Italy). Before that, she worked as biostatistician in the industry, first at Servier for 5 years and then at Novartis Oncology for 4 years. She was responsible for the clinical development and the licensing of medicinal products in neuropsychiatry and leukemia, and her main scientific interests were benefit-risk assessment, network meta-analyses, multiple test procedures, simulation models of time-to-event data and survival analysis in presence of intercurrent events. The development and the promotion of quantitative methods for drug benefit-risk assessments is one of the major topics she considers during her PhD, with the final goal of enhancing decision-making throughout the drug life-cycle. 





About the Presenter: Stephanie Cadour

Gaelle Saint-HilaryGraduated in 2011, Stéphanie Cadour works as a biostatistician at Servier (France) since then. She was initially responsible for the statistical aspects of phase II and III clinical studies conducted in the therapeutic areas of neuropsychiatry and diabetes. She is now working on early phase studies in the field of oncology. In parallel of these activities, Stephanie developed skills on meta-analyses as well as on quantitative approaches for benefit-risk assessment on which she has been working on since 2011.




To access the recording, please visit the Video-on-Demand Library.

Webinars

PSI/EFSPI Webinar: Quantitative benefit-risk assessment using MultiCriteria Decision Analysis (MCDA) and its extensions: practical application

Time: 14:00 - 15:30 UK Time

Presenters: Gaelle Saint-Hilary and Stephanie Cadour

Click here to view the presentation slides.

Click here for the programme and slides.

Abstract

Several quantitative methodologies have been proposed to support decision-making in drug development. In particular, MultiCriteria Decision Analysis (MCDA) is a useful tool to assess the benefit-risk balance of medicines according to the performances of the treatments on several criteria, accounting for the preferences of the decision-makers regarding the relative importance of these criteria. The EMA Benefit-Risk Methodology Project suggested that it is one of the most comprehensive among the quantitative methodologies they considered, and it is also recommended by several highly profiled expert groups. While MCDA requires the exact elicitation of the weights of the criteria according to the preferences of the decision-makers, extended versions of MCDA have been proposed, such as Stochastic Multicriteria Acceptability Analysis (SMAA) and Dirichlet SMAA, where the weights are considered as random variables to account for some uncertainty in the weight assignment.

This webinar proposes a very concrete illustration of MCDA and of the extended models SMAA and Dirichlet SMAA using case-studies. We will present how to derive a benefit-risk utility score for each treatment, how to compare several treatments, how to present the results and how to conduct sensitivity analyses. The differences between the models will be highlighted, and some R code will be presented and shared after the presentation.



About the Presenter: Gaelle Saint-Hilary

Stephanie CadourGaelle Saint-Hilary works in statistics for the pharmaceutical industry since 2006. She is currently completing a PhD on “Quantitative Decision-Making in Drug Development”, sponsored by Servier, at the Polytechnic University of Turin (Italy). Before that, she worked as biostatistician in the industry, first at Servier for 5 years and then at Novartis Oncology for 4 years. She was responsible for the clinical development and the licensing of medicinal products in neuropsychiatry and leukemia, and her main scientific interests were benefit-risk assessment, network meta-analyses, multiple test procedures, simulation models of time-to-event data and survival analysis in presence of intercurrent events. The development and the promotion of quantitative methods for drug benefit-risk assessments is one of the major topics she considers during her PhD, with the final goal of enhancing decision-making throughout the drug life-cycle. 





About the Presenter: Stephanie Cadour

Gaelle Saint-HilaryGraduated in 2011, Stéphanie Cadour works as a biostatistician at Servier (France) since then. She was initially responsible for the statistical aspects of phase II and III clinical studies conducted in the therapeutic areas of neuropsychiatry and diabetes. She is now working on early phase studies in the field of oncology. In parallel of these activities, Stephanie developed skills on meta-analyses as well as on quantitative approaches for benefit-risk assessment on which she has been working on since 2011.




To access the recording, please visit the Video-on-Demand Library.

Careers Meetings

PSI/EFSPI Webinar: Quantitative benefit-risk assessment using MultiCriteria Decision Analysis (MCDA) and its extensions: practical application

Time: 14:00 - 15:30 UK Time

Presenters: Gaelle Saint-Hilary and Stephanie Cadour

Click here to view the presentation slides.

Click here for the programme and slides.

Abstract

Several quantitative methodologies have been proposed to support decision-making in drug development. In particular, MultiCriteria Decision Analysis (MCDA) is a useful tool to assess the benefit-risk balance of medicines according to the performances of the treatments on several criteria, accounting for the preferences of the decision-makers regarding the relative importance of these criteria. The EMA Benefit-Risk Methodology Project suggested that it is one of the most comprehensive among the quantitative methodologies they considered, and it is also recommended by several highly profiled expert groups. While MCDA requires the exact elicitation of the weights of the criteria according to the preferences of the decision-makers, extended versions of MCDA have been proposed, such as Stochastic Multicriteria Acceptability Analysis (SMAA) and Dirichlet SMAA, where the weights are considered as random variables to account for some uncertainty in the weight assignment.

This webinar proposes a very concrete illustration of MCDA and of the extended models SMAA and Dirichlet SMAA using case-studies. We will present how to derive a benefit-risk utility score for each treatment, how to compare several treatments, how to present the results and how to conduct sensitivity analyses. The differences between the models will be highlighted, and some R code will be presented and shared after the presentation.



About the Presenter: Gaelle Saint-Hilary

Stephanie CadourGaelle Saint-Hilary works in statistics for the pharmaceutical industry since 2006. She is currently completing a PhD on “Quantitative Decision-Making in Drug Development”, sponsored by Servier, at the Polytechnic University of Turin (Italy). Before that, she worked as biostatistician in the industry, first at Servier for 5 years and then at Novartis Oncology for 4 years. She was responsible for the clinical development and the licensing of medicinal products in neuropsychiatry and leukemia, and her main scientific interests were benefit-risk assessment, network meta-analyses, multiple test procedures, simulation models of time-to-event data and survival analysis in presence of intercurrent events. The development and the promotion of quantitative methods for drug benefit-risk assessments is one of the major topics she considers during her PhD, with the final goal of enhancing decision-making throughout the drug life-cycle. 





About the Presenter: Stephanie Cadour

Gaelle Saint-HilaryGraduated in 2011, Stéphanie Cadour works as a biostatistician at Servier (France) since then. She was initially responsible for the statistical aspects of phase II and III clinical studies conducted in the therapeutic areas of neuropsychiatry and diabetes. She is now working on early phase studies in the field of oncology. In parallel of these activities, Stephanie developed skills on meta-analyses as well as on quantitative approaches for benefit-risk assessment on which she has been working on since 2011.




To access the recording, please visit the Video-on-Demand Library.

Upcoming Events

PSI Training Course: Effective Leadership – the keys to growing your leadership capabilities

This course will consist of three online half-day workshops. The first will be aimed at building trust, the backbone of leadership and a key to becoming effective. This is key to building a solid foundation. The second will be on improving communication as a technical leader. This workshop will focus on communication strategies for different stakeholders and will involve tips on effective communication and how to develop the skills of active listening, coaching and what improv can teach us about good communication. The final workshop will bring these two components together to help leaders become more influential. This will also focus on how to use Steven Covey’s 7-Habits, in particular Habits 4, 5 and 6, which are called the habits of communication. The workshops will be interactive, allowing you to practice the concepts discussed. There will be plenty of time for questions and discussion. There will also be reflective time where you can think about what you are learning and how you might experiment with it.

PSI Introduction to Industry Training (ITIT) Course - 2026/2027

An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.

PSI Career Young Virtual Event (Q1 2026)

This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.

Inclusive and Impactful Conference Contributions

This webinar brings together three bitesize complementary sessions to help PSI contributors create conference presentations and posters that communicate clearly and inclusively. Participants will explore how to refine their message, prepare materials effectively, and adopt practical habits that support confident, accessible delivery. A focused, supportive session designed to elevate every contribution.

AIMS SIG - Open-Source Lunch Bites

Our monthly webinar series allows attendees to gain practical knowledge and skills in open-source coding and tools, with a focus on applications in the pharmaceutical industry. This month’s session, “Graphics Basics,” will introduce the fundamentals of producing graphics using the ggplot2 package.

Joint PSI/EFSPI Visualisation SIG 'Wonderful Wednesday' Webinars

Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.

Strategic role of statisticians for JCA

Join our Health Technology Assessment (HTA) European Special Interest Group (ESIG) for a webinar on the strategic role of statisticians in the Joint Clinical Assessment (JCA). The introduction of the JCA marks a new era for evidence generation and market access in Europe. As HTA requirements become more harmonized and methodologically demanding, the role of statisticians has evolved far beyond data analysis. Today, statistical expertise is central to shaping clinical development strategies, designing robust comparative evidence, and ensuring that submissions withstand the scrutiny of EU-level assessors. In this webinar, we explore how statisticians contribute strategically to successful JCA outcomes.

Statisticians in the Age of AI: On Route to Strategic Partnership

A 90-minute webinar featuring two case studies from Bayer and Roche demonstrating how statisticians successfully integrated into AI programs, followed by interactive discussion on strategies for elevating statistical expertise in the AI era.

PSI Career Young Virtual Event (Q2 2026)

This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.

PSI Career Young Virtual Event (Q3 2026)

This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.

PSI Career Young Virtual Event (Q4 2026)

This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.

Latest Jobs

GSK - Statistics Director - Vaccines and Infectious Disease

We are seeking an experienced and visionary Statistics Director to join our Team and lead strategic statistical innovation across GSK’s Vaccines and Infectious Disease portfolio.

ICON PLC - Biostatistician II

We are currently seeking a Biostatistician II to join our diverse and dynamic team.

ICON PLC - Pharmacometrician

We are currently seeking a Pharmacometrician to join our diverse and dynamic team.

ICON PLC - Principal Biostatistician

As a Principal Biostatistician, you will lead the statistical strategy and delivery for Phase I–III oncology trials.

ICON PLC - Senior Biostatistician

As a Senior Biostatistician I at ICON, you will play a pivotal role in designing and analyzing clinical trials, interpreting complex medical data, and contributing to the advancement of innovative treatments and therapies.

ICON PLC - Statistical Scientist

As a Statistical Scientist at ICON, you will play a pivotal role in designing and analyzing clinical trials, interpreting complex medical data, and contributing to the advancement of innovative treatments and therapies.

Novartis - Associate Director Biostatistics

We have an exciting opportunity for an Associate Director, Biostatistics to join a passionate team within Advanced Quantitative Sciences – Full Development.

Novartis - Associate Director, Statistical Programming

: We have an exciting opportunity for an Associate Director (AD), Statistical Programming, to join a passionate team within Advanced Quantitative Sciences- Development.

Novartis - Principal Statistical Programmer

We have an exciting opportunity for a Principal Statistical Programmer, to join a passionate team within Advanced Quantitative Sciences – Development.

Novartis - Senior Principal Biostatistician

We are in search of a Senior Principal Biostatistician to join a passionate team within Advanced Quantitative Sciences.

Novartis - Senior Principal Statistical Programmer

We have an exciting opportunity for a Senior Principal Statistical Programmer, to join a passionate team within Advanced Quantitative Sciences – Development.

Pierre Fabre - Clinical Development Safety Statistics Expert M/F

We are seeking a highly skilled and proactive Clinical Development Safety Statistics Expert to join our Biometry Department and the Biometry Leadership Team based in Toulouse (31, Oncopole) or Boulogne (92).

Pierre Fabre - Lead Statistician – Real World Evidence -CDI- M/F

Pierre Fabre Laboratories are hiring a highly skilled and experienced Lead Statistician – Real World Evidence (RWE) to join the Biometry Department, part of the Data Science & Biometry Department, based in Toulouse (Oncopôle) or Boulogne.

Pierre Fabre - Lead Statistician- Clinical Trials M/F

We are seeking a highly skilled and experienced Lead Statistician in Clinical Trials to join our Biometry Department based in Toulouse (31, Oncopole) or Boulogne (92).

Plus-Project - Senior Statistician

We currently have openings for Senior Statisticians based in the UK to join our Employee Owned Biostatistics CRO, Plus-Project.

Veramed - Senior or Principal Statistician - UK/EU (Remote/ Hybrid/ Office)

We have an opportunity for an experienced high level Senior or Principal Statistician to join us on a permanent basis.

Veramed - Senior Statistical Programmer

We are looking for Senior Statistical Programmers in the UK to join Veramed, where you'll deliver high-impact programming solutions in an FSP-style capacity, while advancing your career in a supportive, growth-driven environment.